Evidence map›Paper›PMID 40463715›Full record

ArticleFrontiers in genetics2025

Hao Wu, Liang Yang, Xiaokun Weng

Abstract read
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hao Wu *First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Liang Yang *Department of Neurosurgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai, China.
Xiaokun WengDepartment of Radiotherapy, Lishui People's Hospital, Lishui, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) does not have distinct and highly sensitive biomarkers, making its diagnosis difficult. Consequently, identifying dependable biomarkers is critical, as these indicators can facilitate accurate ESCC diagnosis and enable effective prognostic evaluation. Methods: ESCC datasets (GSE29001, GSE20347, GSE45670, and GSE161533) were sourced from the GEO, and the Limma package identified differentially expressed genes (DEGs). To characterize co-expression network, weighted gene co-expression network analysis (WGCNA) was performed, allowing for the identification of relevant co-expression modules. To assess the biological pathways of intersecting genes, we performed pathway enrichment analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). The Support Vector Machine Recursive Feature Elimination (SVM), along with Least Absolute Shrinkage and Selection Operator (LASSO) regression, was applied to identify clinical biomarkers. Finally, the differences of immune cell infiltration were also detected. Results: 1,019 genes were derived by integrating DEGs with co-expressed module genes. KEGG and GO revealed a strong association between these genes and processes such as chemotaxis and IL-17 signaling pathways. Two hub genes ( Conclusion: Collectively,

Indexed as

ESCCIFI35IFIT3machine learningWGCNA

Identifiers

PMID40463715
PMCPMC12129983

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.